Romuald Seizeur
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Romuald Seizeur has a total of 232 co-authors. Here are the top co-authors by number of shared publications:
- Charlotte Bronnimann
Department of Medical Oncology, CHU St André, Bordeaux, France
10 shared publications - François Ducray
Department of Neuro-Oncology, Hospices Civils de Lyon, Hôpital Neurologique et Neurochirurgical Pierre Wertheimer, 69500 Lyon, France
10 shared publications - Adam Resnick
Center for Data-Driven Discovery in Biomedicine, Children’s Hospital of Philadelphia
9 shared publications - Alexander Drilon
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
9 shared publications - Alexander Gregory Weil
Brain and Development Research Axis, Sainte-Justine Research Center, Montreal, Canada
9 shared publications - Alvaro Lassaletta
Hospital Infantil Universitario Niño Jesús
9 shared publications
Latest Publications
- 20 November 2025
- Published by Elsevier in Neurochirurgie
- Vol. 72 (1) , 101753
Awake surgery and music: Two illustrative cases of frontal resection in pianists
- 20 November 2025
- Published by Elsevier in Neurochirurgie
- Vol. 72 (1) , 101753
Awake surgery and music: Two illustrative cases of frontal resection in pianists
- Open Access
Improving Diagnostic Robustness of Perfusion MRI in Brain Metastases: A Focus on 3D ROI Techniques and Automatic Thresholding
Background: Distinguishing tumor recurrence from radiation necrosis after radiotherapy for brain metastases remains a major diagnostic challenge. Perfusion MRI, particularly the measurement of relative cerebral blood volume (rCBV), is a commonly used technique to differentiate between these two entities. However, variations in the placement of regions of interest (ROIs) affect diagnostic accuracy. This study compares the diagnostic performance of different cerebral perfusion methods, including a novel volumetric 3D ROI method and automatic thresholding, to differentiate tumor recurrence from radiation necrosis. Methods: We retrospectively analyzed data from 23 patients, including 25 brain metastases treated with stereotactic radiotherapy, who were suspected of local recurrence and had histological confirmation via biopsy or surgical resection. Each patient underwent perfusion MRI before surgery. The diagnostic performance of the different ROI methods (manual and 3D) was evaluated using the area under the ROC curve (AUC), as well as sensitivity and specificity measures. An automatic thresholding method was also applied, generating tumor sub-volumes with predefined cut-off values to determine the rCBV threshold most specific for differentiating relapse from necrosis. Results: The 3D ROI method, considering the whole lesion and a healthy ROI in the head of the caudate nucleus, demonstrated superior diagnostic performance (AUC = 0.65), outperforming manual methods (AUC = 0.53). Robustness was moderate, with an intraclass correlation coefficient of 0.60 between Syngo.via and IntelliSpace. Conclusions: The 3D ROI method shows promise in improving diagnostic accuracy in distinguishing tumor recurrence from radiation necrosis. Further studies with standardized protocols and larger populations are needed to validate these results.
Open AccessImproving Diagnostic Robustness of Perfusion MRI in Brain Metastases: A Focus on 3D ROI Techniques and Automatic Thresholding
Background: Distinguishing tumor recurrence from radiation necrosis after radiotherapy for brain metastases remains a major diagnostic challenge. Perfusion MRI, particularly the measurement of relative cerebral blood volume (rCBV), is a commonly used technique to differentiate between these two entities. However, variations in the placement of regions of interest (ROIs) affect diagnostic accuracy. This study compares the diagnostic performance of different cerebral perfusion methods, including a novel volumetric 3D ROI method and automatic thresholding, to differentiate tumor recurrence from radiation necrosis. Methods: We retrospectively analyzed data from 23 patients, including 25 brain metastases treated with stereotactic radiotherapy, who were suspected of local recurrence and had histological confirmation via biopsy or surgical resection. Each patient underwent perfusion MRI before surgery. The diagnostic performance of the different ROI methods (manual and 3D) was evaluated using the area under the ROC curve (AUC), as well as sensitivity and specificity measures. An automatic thresholding method was also applied, generating tumor sub-volumes with predefined cut-off values to determine the rCBV threshold most specific for differentiating relapse from necrosis. Results: The 3D ROI method, considering the whole lesion and a healthy ROI in the head of the caudate nucleus, demonstrated superior diagnostic performance (AUC = 0.65), outperforming manual methods (AUC = 0.53). Robustness was moderate, with an intraclass correlation coefficient of 0.60 between Syngo.via and IntelliSpace. Conclusions: The 3D ROI method shows promise in improving diagnostic accuracy in distinguishing tumor recurrence from radiation necrosis. Further studies with standardized protocols and larger populations are needed to validate these results.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Figure S2. A) Hazard ratio for progression or death according to clinical characteristics. B) Hazard ratio for death according to clinical characteristics. LGG: Low-grade glioma, HGG: High-grade glioma
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Figure S2. A) Hazard ratio for progression or death according to clinical characteristics. B) Hazard ratio for death according to clinical characteristics. LGG: Low-grade glioma, HGG: High-grade glioma
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S4. Other molecular alterations reported.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S4. Other molecular alterations reported.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Data S1. Definition of response, Description of response criteria used by sites to evaluate tumor response, Definition of extend of resection, Definition of extend of resection used by sites.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Data S1. Definition of response, Description of response criteria used by sites to evaluate tumor response, Definition of extend of resection, Definition of extend of resection used by sites.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S1. NTRK fusion type and histology.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S1. NTRK fusion type and histology.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Figure S1. Diagram of population patients.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Figure S1. Diagram of population patients.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S5. Method of NTRK fusion detection as reported by participating centers.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S5. Method of NTRK fusion detection as reported by participating centers.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S3. Survival outcome.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S3. Survival outcome.
- Open Access
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S2. Responses based on clinical assessment for each line of therapy. Non-targeted therapy and TRKi given concurrently in a specific line were excluded.
- 3 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Clinical Characteristics and Outcomes of Central Nervous System Tumors Harboring NTRK Gene Fusions
Supplementary Table S2. Responses based on clinical assessment for each line of therapy. Non-targeted therapy and TRKi given concurrently in a specific line were excluded.